Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biodistribution of 89Zr-coramitug in ATTR-CM
NCT07448623Phase 1Recruiting
- Sponsor
- Novo Nordisk
- Start
- Mar 2026
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of coramitug in transthyretin amyloid cardiomyopathy (ATTR-CM) (2 cohorts), sponsored by Novo Nordisk. Primary endpoints: Mean Standard Uptake Value Ratio in myocardium and Net uptake rate constant in myocardium. Started Mar 2026; status: recruiting.
02
Drugs
coramitug
03
Conditions
transthyretin amyloid cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on NCT07448623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07448623.